1-MPS-disclosures

Agenda | Featured Speakers | Posters: Clinical CategoryResearch Category | Vendors

MPS Spring Meeting | Friday April 16, 2021
Virtual Toolkit for the 21st Century Psychiatrist

Disclosures

Planners
Eric Achtyes, MD Dr. Achtyes discloses the following relationships. Stock: Pfizer, Moderna, Johnson & Johnson, AstraZeneca. Consultant: Alkermes, Janssen, Lunbeck/Otsuka, Roche, Sunovion, Teva. Grant/Research: Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, National Network of Depression Centers, Neurocrine Biosciences, Novartis, Otsuka, Pear Therapeutics, Takeda
Amy Rosinski, MD Reports no financial relationships with commercial interests.
Michael Jibson, MD Reports no financial relationships with commercial interests.
Bill Sanders, MD Reports no financial relationships with commercial interests.
Theresa Toledo, MD Reports no financial relationships with commercial interests.

Presenters
Christopher Spears, MD Reports no financial relationships with commercial interests.
Christina Wichman, MD Reports no financial relationships with commercial interests.
Arash Javanbakht, MD Reports no financial relationships with commercial interests.
Brandon Unruh, MD Reports no financial relationships with commercial interests.
Kiplink Bohnert, MD Reports no financial relationships with commercial interests.
Cheryl Wills, MD Reports no financial relationships with commercial interests.

Meeting Objectives

Participants will have knowledge of how to:

  • Describe data regarding risks to fetus and neonate with psychiatric medication (antidepressants, anxiolytics and mood stabilizers) use during pregnancy and lactation.
  • Outline common guiding principles regarding psychiatric management of perinatal patient.
  • List the indication and barriers to utilization of brexanolone.
  • Describe the underlying neurobiology of trauma and trauma recovery.
  • Understand the current evidence-based PTSD treatments.
  • Recognize consequences of trauma exposure in Middle Eastern refugees in Michigan.
  • Create a differential diagnosis for cognitive and behavioral changes in the geriatric patient population, including some of the less common neurocognitive disorders.
  • Outline the guiding principles of Good Psychiatric Management for borderline personality disorder.
  • Educate patients/parents on the potential risks of cannabis use in terms of brain development.
  • Peform a neurologic exam to assess for movement disorders in patients on psychotropic medication.
  • Manage more simple movement disorders as a result of psychotropic medication.

_____________________________________________